Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Pulmonary Safety Study of CVT-301 in Parkinson's Disease
2014-003799-22Phase 3Completed
- Sponsor
- Civitas Therapeutics
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of levodopa inhalation powder in Parkinson's disease (PD), sponsored by Civitas Therapeutics. Primary endpoint: Pulmonary safety: FEV1 and FEV1/FVC ratio over 12 months. Started Nov 2014; status: completed.
02
Drugs
levodopa inhalation powder
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2014-003799-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003799-22.